Silence Therapeutics plc (SLN)

NASDAQ: SLN · USD

$19.7

-0.07 (-0.3%)· Recorded snapshot

Market cap	1.2B
Revenue (ttm)	615K
Net income (ttm)	-60M
EPS (ttm)	-$3.81
Shares out	60.2M
Volume	2,720,384
Beta	1.45

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 615K
Net income (ttm): -60M
EPS (ttm): -$3.81
Market cap: 1.2B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Manter

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-90.4

P25 n/aP50 n/aP75 n/a

ROIC-60.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All SLN indicators

Market & fundamental data

Available fields

199

Groups with data

Currency

USD

Showing 199 of 199 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001479615
Company name	Silence Therapeutics plc
Country	United Kingdom
Country code	US
CUSIP number	82686Q101
Earnings date	2026-11-09
Earnings time	bmo
Employees	88
Employees change	-28
Employees growth	-24.14%
Enterprise value	$1.1B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1994
Industry	Biotechnology
Is primary listing	No
Is SPAC	No
ISIN number	US82686Q1013
Last 10-K release date	2026-03-05
Last earnings date	2026-08-10
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.2B
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$19.71
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	SLN
Website	https://www.silence-therapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-19.32%
EV/Sales	1,815.59x
FCF / EV yield	-3.79%
FCF yield	-3.56%
Forward EV/Sales	2,133.17x
Forward P/S	2,270.61x
P/B ratio	24.29x
P/S ratio	1,932.57x
Price / tangible book value	42.59x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	85.85%
Operating margin	-10,475.61%
Pretax margin	-9,748.13%
Profit per employee	$-681,284
Revenue per employee	$6,989
ROA	-29.65%
ROA (5Y)	-26.78%
ROCE	-68.76%
ROE	-90.41%
ROE (5Y)	-218.57%
ROIC	-60.67%
SBC / revenue	1,008.78%
Tax / revenue	0.33%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	2
EPS growth years	0
Gross profit growth	-97.53%
Gross profit growth 3Y	-69.74%
Gross profit growth 5Y	-34.01%
Net income growth quarters	2
Net income growth years	0
Revenue growth	-97.74%
Revenue growth 3Y	-74.33%
Revenue growth 5Y	-46.52%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-3,000
Depreciation and amortization	$483,000
EBIT	$-64.4M
EBITDA	$-63.9M
EPS	$-3.81
FCF per share	$-0.70
Financing cash flow	$2,000
Free cash flow	$-42.3M
Free cash flow minus SBC	$-48.5M
Gross profit	$528,000
Income taxes	$2,000
Investing cash flow	$72.9M
Net cash flow	$30.3M
Net income	$-60M
Operating cash flow minus SBC	$-48.5M
Operating income	$-64.4M
Revenue	$615,000
Stock-based compensation	$6.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-6.32
Book value per share	$0.81
Debt / equity	0
Goodwill	$10.3M
Long-term assets	$12.1M
Long-term liabilities	$55.2M
Net cash (debt)	$71.9M
Net cash / market cap	6.05%
Net cash growth	-36.98%
Net debt / equity	-1.87
Piotroski F-Score	2
Property, plant and equipment	$1.4M
Shareholders' equity	$38.5M
Tangible book value	$27.9M
Tangible book value per share	$0.59
Total assets	$106.4M
Total cash	$72.1M
Total debt	$112,000
Total liabilities	$67.9M
WACC	12.2%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0
Current assets	$94.3M
Current liabilities	$12.7M
Current ratio	7.42
Net working capital	$9.6M
Quick ratio	6.4
Working capital	$81.6M
Working capital turnover	0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.09%
Dividend yield	0%
Shareholder yield	-0.09%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$10.06
1D price change	-0.35%
1M price change	76.43%
1M total return	76.43%
1W price change	0.59%
1W total return	0.59%
1Y price change	176.26%
1Y return CAGR	176.45%
1Y total return	176.26%
20-day SMA	$13.68
200-day SMA	$8.92
3M price change	63.42%
3M total return	63.42%
3Y price change	177.04%
3Y return CAGR	40.44%
3Y total return	177.04%
50-day SMA	$13.23
50-day SMA vs 200-day SMA	50over200
52-week high	$19.87
52-week high date	2026-10-26
52-week low	$4.19
52-week low date	2026-02-12
5Y price change	-9.52%
5Y return CAGR	-1.98%
5Y total return	-9.52%
6M price change	152.24%
6M total return	152.24%
All-time high	$35.00
All-time high date	2021-05-28
All-time low	$1.97
All-time low date	2025-04-10
Average true range (ATR)	$0.87
Average volume	5.9M
Beta (1Y)	1.72
Beta (2Y)	1.4
Beta (5Y)	1.45
Change from 52-week high	-0.78%
Change from 52-week low	370.41%
Change from all-time high	-43.64%
Change from all-time low	901.27%
Change from open	-0.2%
Day's gap	-0.15%
Dollar volume	$53.6M
High price	$19.77
Low price	$19.71
Monthly RSI	67.27
Open price	$19.75
Position in 52-week range	0%
Premarket change	-0.1%
Premarket close	$19.78
Premarket price	$19.76
Premarket volume	353
Previous close	$19.78
Price vs 150-day SMA	96.09%
Price vs 20-day SMA	44.23%
Price vs 200-day SMA	121.21%
Price vs 50-day SMA	49.15%
Relative volume	0.46
RSI	79.3
Sharpe ratio	1.16
Sharpe ratio (3Y)	0.73
Sharpe ratio (5Y)	0.37
Sortino ratio	3.67
Sortino ratio (3Y)	1.57
Sortino ratio (5Y)	0.74
Volume	2.7M
Weekly RSI	71.72
YTD price change	224.42%
YTD total return	224.42%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	48.2M
Float percentage	80.12%
Shares change (QoQ)	0.01%
Shares change (YoY)	0.09%
Shares held by insiders	14.84%
Shares held by institutions	38.35%
Shares outstanding	60.2M
Short % of shares	5.02%
Short ratio	3 days

Deeper analysis on SLN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this SLN report

Is a complete SLN research report available?

No complete published report is available for Silence Therapeutics plc (SLN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Silence Therapeutics plc (SLN)

Price

Financial snapshot

Fair-value bridge

Latest news · SLN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All SLN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on SLN

Frequently asked questions